A Safety and Efficacy Study of FCR001 vs Standard of Care in de Novo Living Donor Kidney Transplantation
- Conditions
- Transplanted Organ Rejection
- Interventions
- Biological: FCR001
- Registration Number
- NCT03995901
- Lead Sponsor
- Talaris Therapeutics Inc.
- Brief Summary
A randomized controlled study to evaluate the safety, efficacy, and overall benefit of FCR001 cell therapy in de novo living donor renal transplantation.
- Detailed Description
The purpose of this randomized (2:1) controlled study is to evaluate the safety, efficacy and overall benefit of FCR001 cell therapy in first or second de novo living donor renal transplantation relative to a standard-of-care control immunosuppression regimen of antibody induction, tacrolimus, mycophenolate, and corticosteroids.
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 15
- Recipient age ≥18 years.
- Donor age ≥18 and ≤60 years at time of signing informed consent.
- Recipients of a first or second living donor kidney transplant
- Donor willing to undergo mobilization, apheresis and 12-month safety follow-up and meet all local standard eligibility criteria to donate stem cells for allogeneic transplantation.
- Recipient meets all local standard eligibility criteria for allogeneic stem cell transplant.
- Donors must be deemed eligible as per the requirements of 21CFR1271.
Main Recipient and Donor
- Recipient and donor who are identical twins.
- Recipient or donor with history of malignancy or premalignant syndrome (e.g., myelodysplastic syndrome, monoclonal gammopathy of renal significance [MGRS], monoclonal gammopathy of unknown significance [MGUS]) of any organ system (other than localized basal cell carcinoma of the skin or in-situ cervical cancer), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.
- Recipient or donor with known bone marrow aplasia.
Main Recipient-only Exclusion Criteria:
- Multi-organ or stem cell transplant recipient.
- Calculated panel reactive antibodies >80%.
- Recipient is blood type ABO incompatible with donor.
- Presence of donor-specific antibodies (DSA) (positive result) at any time pre-transplant.
- Recipient who is human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) positive.
- Recipient with any baseline condition requiring or anticipated will require chronic or intermittent use of systemic steroids or other IS (eg, autoimmune disease, asthma) throughout the course of the study.
- Recipient with a BMI < 18 or > 35 kg/m2.
- Recipient requiring systemic anticoagulation, (eg, for hyper-coagulation disorders, deep vein thrombosis, atrial fibrillation) that cannot be temporarily interrupted which would preclude renal biopsy.
Main Donor-only Exclusion Criteria:
- Biologically unrelated (i.e., no genetic relationship) female donor transplant to male recipient.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description FCR001 FCR001 FCR001 is a cryopreserved allogeneic stem cell therapy derived from mobilized peripheral blood of the kidney donor that is delivered as a single dose with a non- myeloablative conditioning regimen. FCR001 contains the donor's CD34+ cells, facilitating cells, and αβ T cells.
- Primary Outcome Measures
Name Time Method Proportion of FCR001 recipients who are free from immunosuppression (IS), without biopsy proven acute rejection (BPAR) at 24 months post-transplant 24 months post-transplant Free from IS is defined as not taking any immunosuppression medications and not having to take immunosuppression medications since their withdrawal.
Biopsy proven acute rejection is defined as Grade ≥1A according to the Banff 2017 Classification of Antibody-Medicated Rejection and T Cell-Mediated Rejection in Renal Allografts (Haas et al 2018).
- Secondary Outcome Measures
Name Time Method To describe the incidence and severity of AEs (including infections) and SAEs among FCR001 donors Month 24, 36, and 60 Allograft function (eGFR by MDRD4) and change in eGFR from Month 1 to Month 24, 36, and Month 60, by treatment Month 1 (post-transplant) to Month 24, 36, and Month 60 Slope and difference in slope of estimated glomerular filtration rate (eGFR) by Modification of Diet in Renal Disease (MDRD4) over time to Month 24, 36, and 60, by treatment Month 24, 36, and 60 Incidence of de novo donor-specific antibodies Months 12, 24, 36 and 60 Incidence or worsening of abnormal histologic findings of cellular or antibody-mediated chronic rejection, chronic glomerulopathy, tubular atrophy and interstitial fibrosis, C4d, calcineurin inhibitor induced damage, disease recurrence, BK nephropathy Months 12, 24, 36 and 60 Incidence of renal replacement therapy by treatment group Months 12, 24, 36 and 60 Change in renal function by Modification of Diet in Renal Disease (MDRD4) from post-transplant baseline (Month 1) to Month 24 in FCR001 recipients 24 months post-transplant Allograft function (eGFR) and change in renal allograft function from Month 1 to Months 24, 36 and 60 by treatment group, using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula Month 1 (post transplant) to Month 24, 36, and Month 60 Time to the event for the composite of BPAR, graft loss, death or lost to follow-up and for each component, by treatment group Month 1 (post transplant) to Month 6, 12, 24, 36, and 60 Incidence of composite endpoint of BPAR, graft loss, or death and lost to follow-up, by treatment group Months 12, 24, 36 and 60 Incidence of BPAR and treated BPAR by severity, type, and steroid-resistance, by treatment group Months 12, 24, 36 and 60 Incidence of BK viremia, viruria, infection, and nephropathy by treatment Months 12, 24, 36 and 60 Subject quality of life according to End-Stage Renal Disease Symptom Checklist (ESRD-SCL) will be analyzed descriptively by treatment group Months 12, 24, 36 and 60 Incidence and duration of hospitalization and readmission, according to type of ward/unit Months 12, 24, 36 and 60 Incidence of acute rejection, death, renal graft loss, and lost to follow-up between FCR001 recipients who did not achieve durable chimerism or the ability to wean or remain off immunosuppression vs. the control arm Month 24, 36, and 60 Proportion of FCR001 recipients free from IS, without BPAR, at Month 36 and 60 Month 36 and 60 post transplant iBox predicted allograft survival Months 12 and 24 post-transplant The incidence of autologous infusions in FCR001 recipients Month 6, 12, 24, 36, and 60 The correlation of donor chimerism with freedom from IS)in FCR001 recipients will be described Month 6, 12, 24, 36, and 60 Incidence of composite endpoint of BPAR, graft loss or death, by treatment group Months 12, 24, 36 and 60 Incidence of acute rejection Months 12, 24, 36 and 60 Incidence of BPAR or eGFR <50 mL/min by treatment group Months 12, 24, 36 and 60 The incidence of engraftment syndrome in FCR001 recipients Month 6, 12, 24, 36, and 60 The time to neutrophil and platelet recovery in FCR001 recipients Month 6, 12, 24, 36, and 60 The incidence of donor chimerism and level of chimerism by study visit in FCR001 recipients will be described Month 6, 12, 24, 36, and 60 Categorical distribution of eGFR according to chronic kidney disease CKD staging classification by treatment Months 12, 24, 36 and 60 Incidence of the adverse events of special interest (proteinuria, neurotoxicity, anemia, diabetes, hypertension, dyslipidemia, opportunistic infections, major adverse cardiovascular events, and malignancies Months 12, 24, 36 and 60 Graft and patient survival and eGFR in FCR001 recipients who are only transiently chimeric Month 24, 36, and 60 Incidence and severity of adverse events (AEs; including infections), serious adverse events (SAEs) and AEs leading to study and/or regimen discontinuation Months 12, 24, 36 and 60 Urinary protein and albumin excretion, estimated by urinary protein/creatinine and urinary albumin/creatinine ratios by treatment group Months 12, 24, 36 and 60 Subject quality of life according to 36-Item Short Form Health Survey (SF-36) will be analyzed descriptively by treatment group Months 12, 24, 36 and 60 The incidence of blood component transfusions in FCR001 recipients Month 6, 12, 24, 36, and 60 The incidence of acute and chronic Graft versus Host Disease (GvHD) in FCR001 recipients will be described Month 6, 12, 24, 36, and 60
Trial Locations
- Locations (16)
Hospital of the University of Pennsylvania
🇺🇸Philadelphia, Pennsylvania, United States
Baylor University Medical Center
🇺🇸Dallas, Texas, United States
Mayo Clinic
🇺🇸Rochester, Minnesota, United States
Scripps Clinic
🇺🇸La Jolla, California, United States
University of California, San Francisco
🇺🇸San Francisco, California, United States
Georgetown University Hospital
🇺🇸Washington, District of Columbia, United States
Northwestern Memorial Hospital
🇺🇸Chicago, Illinois, United States
The University of Michigan Hospitals & Health System
🇺🇸Ann Arbor, Michigan, United States
University of Minnesota Medical Center
🇺🇸Minneapolis, Minnesota, United States
University of Nebraska Medical Center
🇺🇸Omaha, Nebraska, United States
Duke University Medical Center
🇺🇸Durham, North Carolina, United States
New York-Presbyterian/Weill Cornell
🇺🇸New York, New York, United States
The Ohio State University Wexner Medical Center
🇺🇸Columbus, Ohio, United States
Oregon Health & Science University
🇺🇸Portland, Oregon, United States
UT Southwestern Medical Center
🇺🇸Dallas, Texas, United States
Virginia Commonwealth University
🇺🇸Richmond, Virginia, United States